Stran je namenjena samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji.

Search

Menu

Close

PrijavaOdjava
Naša zdravilaTerapevtska področjaMedia CenterMedia CenterDogodkiGradivaVideo vsebinePovežimo sePovežimo seKontaktirajte nasMedicinske informacije družbe Pfizer

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Recommended by [Local body] for routine vaccination1,2Complete all 4 doses on time to help babies build an optimal Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine) immune response1,2*†‡

[Local body] recommends Prevenar 20™ for routine infant vaccination using a 4-dose schedule to reduce morbidity and other serious consequences from invasive pneumococcal disease (IPD) under 2 years of age.2

Prevenar 20™ can be coadministered with the [Local body]-recommended infant immunisation schedule.1,2
Example TextThe first dose may be given as early as 6 weeks of age.1The recommended dosing interval for the first, second, and third doses is at least 4 weeks.1The booster dose should be administered at approximately 11 to 15 months of age.1

Each dose of Prevenar 20™ is 0.5 mL.1

The United States Advisory Committee on Immunization Practices (ACIP) recommends transitioning babies to Prevenar 20™ at any point of a series started with Prevenar 13®2Catchup dosing induces immune responses to the additional serotypes covered by Prevenar 20™1,3,4Children 7 months to less than 18 years of age not yet vaccinated with Prevenar 13®

Unvaccinated patients

 Children 15 months to less than 18 years of age previously immunised with Prevenar 13®

Previously immunised patients

Prevenar 20™ offers the broadest pneumococcal conjugate vaccine (PCV) serotype coverage, helping to protect preterm infants, who are at higher risk for pneumococcal disease, against the 20 serotypes in the vaccine.1,3-5Preterm infants

[Local body] recommends vaccination with Prevenar 20™ for preterm infants1,2

 Children with underlying health conditions

Prevenar 20™ offers the broadest PCV serotype coverage for groups at higher risk for pneumococcal disease1-4

[Local body] recommends vaccination with Prevenar 20™ for children with underlying health conditions, including sickle cell disease and HIV1,2

Other conditions include2:

  • Cerebrospinal fluid leak
  • Chronic heart disease
  • Chronic kidney disease
  • Chronic liver disease
  • Chronic lung disease (including moderate persistent or severe persistent asthma)
  • Cochlear implant
  • Diabetes mellitus
  • Immunocompromising conditions (on maintenance dialysis or with nephrotic syndrome; congenital or acquired asplenia or splenic dysfunction; congenital or acquired immunodeficiencies; diseases and conditions treated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and solid organ transplant; HIV infection; and sickle cell disease or other hemoglobinopathies)
Given at least 8 weeks after last PCV doseHIV=human immunodeficiency virus.Babies who have undergone haematopoietic stem cell transplant (HSCT)

[Local body] recommends vaccination with Prevenar 20™ for babies who have undergone HSCT1,2
Prevenar|| vaccines have been used to vaccinate nearly 300 million babies, including those who are preterm, have underlying health conditions, or are immunocompromised.1,2,6
Prevenar includes Prevenar® (Pneumococcal 7-valent Conjugate Vaccine) and Prevenar 13®. In [Country], Prevenar® (PCV7) was available from 2001 to 2010, and Prevenar 13® has been available since 2010.3,7,8 Access details for using and ordering Prevenar 20™ LoadingReferences:Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Hjuler T, Wohlfahrt J, Simonsen J, et al. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis. 2007;44(8):1051-1056.Chapman R, Sutton K, Dillon-Murphy D, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis. Vaccine. 2020;38(45):7138-7145.Prevenar® (Pneumococcal 7-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2011.Local vaccine availability dates.
PP-PNR-GLB-0425 March 2024
PfizerPro računPfizerPro račun

Za dostop do dodatnih gradiv, vsebin in prejemanje sporočil o zdravilih in cepivih družbe Pfizer

VpisRegistracijaRačunOdjava

To spletno mesto je namenjeno samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji. Če se uvrščate med širšo javnost in bi želeli dostopati do informacij o določenem zdravilu, se, prosimo, obrnite na vašega zdravnika ali farmacevta.

 

To spletno stran vam ponuja Pfizer, podružnica Ljubljana.

 

Avtorske pravice 2022 Pfizer, podružnica Ljubljana. Vse pravice pridržane.


Davčna številka: SI 17966086

PP-UNP-SVN-0142, datum priprave: september 2023
Zapuščate PfizerPro
​
Zapuščate spletno mesto, ki ga upravlja Pfizer. Povezave do vseh zunanjih spletnih mest so na voljo kot vir za naše obiskovalce. Pfizer ne prevzema odgovornosti za vsebino spletnih mest, ki niso v lasti in upravljanju družbe Pfizer.
 
PP-UNP-SVN-0142
datum priprave: september 2023
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​